THE STRUCTURE OF THE GENETIC POLYMORPHISMS IN PATIENTS WITH METABOLIC SYNDROME AND A COMPLICATED PREGNANCY IN HISTORY

Objective. To analyze the structure of the gene polymorphisms of hemostasis, platelet receptors and enzymes of the folate cycle in patients with metabolic syndrome (MS) and a complicated pregnancy in history.

Materials and Methods. The study included 115 patients with MS. Of these, group 1 (64 patients) had a complicated course of pregnancy in anamnesis and group 2 (51 patient) with no pregnancies in anamnesis. The control group consisted of 50 somatically healthy mothers. All the patients were carried out molecular analysis of gene polymorphisms of the hemostatic polymorphisms of platelet receptor genes, polymorphisms of genes of folate cycle enzymes by polymerase chain reaction.

Results. In all patients with MS was identified pathology of genes of hemostasis, platelet receptors or enzymes of the folate cycle, and in all cases attended a multigenic (more than two defect genes) form of pathology. In the study, the patients with MS was significantly higher frequency of polymorphism in the gene for inhibitor of tissue plasminogen activator, in the gene of tissue plasminogen activator, fibrinogen gene, in the gene for angiotensin-converting enzyme gene of the receptor of angiotensin II 1 type. Gene polymorphisms of platelet receptors were also found significantly more often in patients with MS. Results of the study of folate cycle enzymes genes showed the prevalence of pathological polymorphisms in this group of genes in the genotype of patients with MS. In patients with MS and a complicated pregnancy in history was revealed not only a large frequency of occurrence of a pathological gene polymorphisms, but also the predominance in the structure the homozygous forms of these polymorphisms.

Conclusion. Thus, it becomes obvious pathogenetic role of latent thrombophilic states in the development of various obstetric complications in patients with MS and the reason underlying this condition is a multigenic structure of the gene polymorphisms of hemostasis, platelet receptors and enzymes of the folate cycle in all MS patients.

1. Makatsariya A.D., Pshenichnikova E.B., Pshenichnikova T.B., Bitsadze V.O. Metabolic syndrome and thrombophilia in obstetrics and gynecology [Metabolicheskii sindrom i trombofiliya v akusherstve i ginekologii (in Russian)]. Moscow. 2006; 480 s.

2. Alessi M.C., Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thrombosis and Haemostasis. 2008; 99: 995-1000.

3. Anfossi G., Russo I., Trovati M. Platelet dysfunction in central obesity. Nutrition, Metabolism, and Cardiovascular Diseases. 2009; 19: 440-419.

4. Badimon L., Hernandez Vera R., Vilahur G. Atherothrombotic risk in obesity. Hamostaseologie. 2013; 33: 259-68.

5. Bates S.M., Greer I.A., Pabinger I. et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 844-886.

6. Franchini M., Targher G., Montagnana M., Lippi G. The metabolic syndrome and the risk of arterial and venousthrombosis. Thrombosis Research. 2008; 122: 727-735.

7. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113: 1888-1904.

8. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010; 314: 1-16.

9. Mina A., Favaloro E.J., Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review. Seminars in Thrombosis and Hemostasis. 2007; 33: 798-809.

10. Nieuwdorp M., Stroes E.S., Meijers J.C., Buller H. Hypercoagulability in the metabolic syndrome. Current Opinion in harmacology. 2005; 5: 155-159.

11. Palomo I., Alarcon M., Moore-Carrasco R., Argiles J.M. Hemostasis alterations in metabolic syndrome. International Journal of Molecular Medicine. 2006; 18: 969-974.

12. Randriamboavonjy V., Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care. 2009; 32: 528-530.

13. Robertson L., Wu O., Langhorne P. et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006; 132: 171-196.